|   In the News

Q32 debuts with $46M to ‘rebalance’ innate and adaptive immunity


Many autoimmune diseases are treated with immunosuppressive drugs to rein in an immune system that has turned on the body’s own tissues. Problem is, that approach doesn’t just tamp down the immune response in affected tissues—it affects immune cells throughout the body. Enter Q32 Bio, which is working on a new generation of treatments for autoimmune and inflammatory diseases.

Read more.